aav5-hrkp.rpgr
Gene therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 12, 2023 (NCT05926583)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- X-linked retinitis pigmentosa GTPase regulatorSupplementation
supplementation - rpgr
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06646289 | Phase 2 | Oct 11, 2024 | — |
| NCT05926583 | Phase 3 | Sep 12, 2023 | Janssen Pharmaceutica NV |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1